CAS 181467-56-1: 5-{[1-({[(4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl]oxy}carbonyl)piperidin-4-yl]amino}pentanoic acid

Applications A major metabolite of Irinotecan. References Canal, P., et al.: J. Clin. Oncol., 14, 2688 (1996), Haaz, M., et al.: Cancer Res., 58, 468 (1998), Kehrer, D., et al.: Clin. Cancer Res., 6, 3451 (2000), Hanioka, N., et al.: Xenobiotica, 31, 687 (2001), Satoh, T., et al.: Drug Metab. Dispos., 30, 488 (2002),

7-Ethyl-10-(4-N-aminopentanoic acid)-1-piperidino)carbonyloxycamptothecin (APC) is a potent inhibitor of secretory phospholipase A2, which has been shown to be involved in the pathogenesis of several diseases. APC also inhibits the production of β-catenin and has been shown to inhibit tumor growth in vivo. Furthermore, APC has been shown to have anti-cancer properties against squamous carcinoma cells and may be an effective chemotherapeutic agent for this type of cancer. The mechanism of action for APC is not well understood, but it may involve inhibition of DNA polymerase α or δ, or binding to the ribosomal protein S6 kinase 1.

RPR121056 is a Irinotecan metabolite, which is generated by CYP3A4. Irinotecan is an antineoplastic agent that inhibits topoisomerase type I.